Total Funding
71
64
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
20358
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
- Christine Cvijic: President & CFO
- Christy Shafer: Chief Commercial OfficerPast Role: Avidity Biosciences, Senior Vice President and General Manager - North America
About the Company
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that
improves quality of life.
Women Founded
Women Led
